- Published on
Infectious Disease and Microbiology – Atypical Mycobacteria (Nontuberculous Mycobacteria)
Atypical mycobacteria refer to infections caused by nontuberculous mycobacteria (NTM), a diverse group of environmental mycobacterial species distinct from Mycobacterium tuberculosis. In children, atypical mycobacteria should be considered in cases of unilateral cervical lymphadenitis, particularly in those aged 1–5 years. The swelling typically involves the anterior cervical chain, enlarges gradually, and may form fistulas through the skin. Enlarged lymph nodes are often painless, and systemic symptoms are uncommon. Most pediatric cases are caused by Mycobacterium avium complex (MAC), while M. scrofulaceum and M. tuberculosis are less frequent causes. Approximately 300 cases of MAC lymphadenitis occur annually in the United States. Overall prevalence ranges from 1 to 7.2 cases per 100,000 persons in the US, varying by region, and about half of NTM isolates represent true pathogens.
Risk factors for NTM infection include advanced age, immunosuppression, HIV infection with low CD4 counts, interferon-gamma deficiencies, and underlying structural lung disease such as bronchiectasis or chronic obstructive pulmonary disease. Genetic defects such as IFN-γ receptor 1 (IFNγR1) or interleukin-12 receptor β1 (IL-12βR1) deficiency predispose individuals to disseminated disease. In patients with AIDS and CD4 counts below 100 cells/mm³, primary prophylaxis with weekly azithromycin 1200 mg is recommended; alternatives include clarithromycin or rifabutin.
NTM are widely found in soil and water, including hot tubs and tap water. Human-to-human transmission has not been documented. Infection occurs primarily through ingestion or inhalation rather than reactivation of latent disease. Granuloma formation results from interactions between macrophages, lymphocytes, and natural killer cells. Disseminated infection arises from uncontrolled localized disease, especially in immunocompromised hosts. These organisms are aerobic, non–spore-forming bacilli with mycolic acid–containing cell walls. They are categorized by growth rate into rapid-growing mycobacteria (e.g., M. fortuitum, M. chelonae/abscessus, M. smegmatis), intermediate growers (e.g., M. marinum, M. gordonae), and slow-growing organisms (e.g., MAC, M. kansasii, M. xenopi, M. scrofulaceum, M. haemophilum, M. ulcerans).
Clinical syndromes include pulmonary disease, lymphadenitis, skin and soft tissue infection, osteoarticular disease, catheter-related infection, and disseminated disease. Pulmonary infection typically presents with chronic productive cough and may progress to weight loss, fatigue, dyspnea, hemoptysis, and chest pain. Soft tissue infections often follow trauma, surgery, or aquatic exposure and appear as papular or ulcerative lesions that may spread along lymphatics. Lymphadenitis usually manifests as painless or mildly tender enlargement of submandibular or jugular lymph nodes. Disseminated disease, most commonly seen in advanced HIV infection, presents with fever, fatigue, anorexia, and laboratory abnormalities such as pancytopenia or elevated alkaline phosphatase.
Diagnosis requires correlation of clinical, radiographic, and microbiologic findings because NTM may represent colonization rather than true infection. In pulmonary disease, chest imaging may show upper-lobe cavitary lesions, nodular or reticulonodular infiltrates, or adenopathy. Cavitary disease is common in MAC pulmonary infections and typically involves thin-walled cavities measuring 2–4 cm. At least three sputum samples (or bronchoalveolar lavage specimens) should be obtained for acid-fast bacillus smear and culture. Mycobacterial blood cultures are positive in approximately 90% of disseminated MAC cases. Tissue biopsy demonstrating granulomas with giant cells and acid-fast bacilli supports localized infection, whereas well-formed granulomas may be absent in disseminated disease. Definitive identification and susceptibility testing should be performed at specialized laboratories.
Treatment depends on the species and site of infection and often requires prolonged multidrug therapy. Pulmonary MAC is treated with rifampin, ethambutol, and a macrolide (azithromycin or clarithromycin), sometimes with an aminoglycoside for severe disease. Therapy continues for at least 12 months after cultures become negative. Pulmonary infection with M. kansasii is treated with isoniazid, rifampin, and ethambutol. Rapid-growing mycobacteria causing soft tissue infections are treated with two active agents based on susceptibility testing, such as trimethoprim–sulfamethoxazole, doxycycline, levofloxacin, or clarithromycin. Severe M. abscessus infections may require amikacin combined with clarithromycin and cefoxitin or imipenem. Disseminated MAC in HIV patients is treated with a macrolide plus ethambutol, with consideration of adding rifampin.
Surgical management may be necessary in selected cases. Resection of affected lymph nodes in MAC lymphadenitis achieves cure in approximately 90% of pediatric cases without antimicrobials. Lung resection may be considered in localized refractory pulmonary disease. Incision and drainage are often required for soft tissue infections.
Long-term follow-up is essential because therapy may last months to years and drug toxicities are common. Patients require regular laboratory monitoring, evaluation for drug–drug interactions, and sometimes therapeutic drug monitoring. Prognosis depends on the infecting species, the site of disease, and the host’s immune status. Complications include ulceration and fistula formation in lymphadenitis and, rarely, gastrointestinal complications such as intussusception or obstruction in disseminated MAC.
Atypical mycobacteria refer to infections caused by nontuberculous mycobacteria (NTM), a diverse group of environmental mycobacterial species distinct from Mycobacterium tuberculosis. In children, atypical mycobacteria should be considered in cases of unilateral cervical lymphadenitis, particularly in those aged 1–5 years. The swelling typically involves the anterior cervical chain, enlarges gradually, and may form fistulas through the skin. Enlarged lymph nodes are often painless, and systemic symptoms are uncommon. Most pediatric cases are caused by Mycobacterium avium complex (MAC), while M. scrofulaceum and M. tuberculosis are less frequent causes. Approximately 300 cases of MAC lymphadenitis occur annually in the United States. Overall prevalence ranges from 1 to 7.2 cases per 100,000 persons in the US, varying by region, and about half of NTM isolates represent true pathogens.
Risk factors for NTM infection include advanced age, immunosuppression, HIV infection with low CD4 counts, interferon-gamma deficiencies, and underlying structural lung disease such as bronchiectasis or chronic obstructive pulmonary disease. Genetic defects such as IFN-γ receptor 1 (IFNγR1) or interleukin-12 receptor β1 (IL-12βR1) deficiency predispose individuals to disseminated disease. In patients with AIDS and CD4 counts below 100 cells/mm³, primary prophylaxis with weekly azithromycin 1200 mg is recommended; alternatives include clarithromycin or rifabutin.
NTM are widely found in soil and water, including hot tubs and tap water. Human-to-human transmission has not been documented. Infection occurs primarily through ingestion or inhalation rather than reactivation of latent disease. Granuloma formation results from interactions between macrophages, lymphocytes, and natural killer cells. Disseminated infection arises from uncontrolled localized disease, especially in immunocompromised hosts. These organisms are aerobic, non–spore-forming bacilli with mycolic acid–containing cell walls. They are categorized by growth rate into rapid-growing mycobacteria (e.g., M. fortuitum, M. chelonae/abscessus, M. smegmatis), intermediate growers (e.g., M. marinum, M. gordonae), and slow-growing organisms (e.g., MAC, M. kansasii, M. xenopi, M. scrofulaceum, M. haemophilum, M. ulcerans).
Clinical syndromes include pulmonary disease, lymphadenitis, skin and soft tissue infection, osteoarticular disease, catheter-related infection, and disseminated disease. Pulmonary infection typically presents with chronic productive cough and may progress to weight loss, fatigue, dyspnea, hemoptysis, and chest pain. Soft tissue infections often follow trauma, surgery, or aquatic exposure and appear as papular or ulcerative lesions that may spread along lymphatics. Lymphadenitis usually manifests as painless or mildly tender enlargement of submandibular or jugular lymph nodes. Disseminated disease, most commonly seen in advanced HIV infection, presents with fever, fatigue, anorexia, and laboratory abnormalities such as pancytopenia or elevated alkaline phosphatase.
Diagnosis requires correlation of clinical, radiographic, and microbiologic findings because NTM may represent colonization rather than true infection. In pulmonary disease, chest imaging may show upper-lobe cavitary lesions, nodular or reticulonodular infiltrates, or adenopathy. Cavitary disease is common in MAC pulmonary infections and typically involves thin-walled cavities measuring 2–4 cm. At least three sputum samples (or bronchoalveolar lavage specimens) should be obtained for acid-fast bacillus smear and culture. Mycobacterial blood cultures are positive in approximately 90% of disseminated MAC cases. Tissue biopsy demonstrating granulomas with giant cells and acid-fast bacilli supports localized infection, whereas well-formed granulomas may be absent in disseminated disease. Definitive identification and susceptibility testing should be performed at specialized laboratories.
Treatment depends on the species and site of infection and often requires prolonged multidrug therapy. Pulmonary MAC is treated with rifampin, ethambutol, and a macrolide (azithromycin or clarithromycin), sometimes with an aminoglycoside for severe disease. Therapy continues for at least 12 months after cultures become negative. Pulmonary infection with M. kansasii is treated with isoniazid, rifampin, and ethambutol. Rapid-growing mycobacteria causing soft tissue infections are treated with two active agents based on susceptibility testing, such as trimethoprim–sulfamethoxazole, doxycycline, levofloxacin, or clarithromycin. Severe M. abscessus infections may require amikacin combined with clarithromycin and cefoxitin or imipenem. Disseminated MAC in HIV patients is treated with a macrolide plus ethambutol, with consideration of adding rifampin.
Surgical management may be necessary in selected cases. Resection of affected lymph nodes in MAC lymphadenitis achieves cure in approximately 90% of pediatric cases without antimicrobials. Lung resection may be considered in localized refractory pulmonary disease. Incision and drainage are often required for soft tissue infections.
Long-term follow-up is essential because therapy may last months to years and drug toxicities are common. Patients require regular laboratory monitoring, evaluation for drug–drug interactions, and sometimes therapeutic drug monitoring. Prognosis depends on the infecting species, the site of disease, and the host’s immune status. Complications include ulceration and fistula formation in lymphadenitis and, rarely, gastrointestinal complications such as intussusception or obstruction in disseminated MAC.
0 Comments
